Hof Danielle, von Eckardstein Arnold
Unilabs, Dübendorf, Dübendorf, Switzerland.
Institute for Clinical Chemistry, University Hospital Zurich, Zürich, Switzerland.
Methods Mol Biol. 2019;1929:645-662. doi: 10.1007/978-1-4939-9030-6_40.
Nowadays, measurement of cardiac troponins (cTn) in patient plasma is central for diagnosis of patients with acute coronary syndrome (ACS). High-sensitivity (hs) immunoassays have been developed that can very precisely record slightly elevated and rising plasma concentrations of cTn very early after onset of clinical symptoms. Algorithms integrate measurements of hs-cTn at onset of clinical symptoms of acute myocardial infarction (AMI), and 1 or 3 h after onset, to rule-in and rule-out AMI patients. More and more point-of-care (POC) cTn assays conquer the diagnostic market, but thorough clinical validation studies are required before potential implementation of such POC tests into hospital settings. This review provides an overview of the technical aspects, as well as diagnostic and prognostic use of cardiac troponins in AMI patients and in the healthy population.
如今，检测患者血浆中的心肌肌钙蛋白（cTn）对于急性冠状动脉综合征（ACS）患者的诊断至关重要。已经开发出高灵敏度（hs）免疫测定法，能够在临床症状出现后很早的时候非常精确地记录cTn血浆浓度的轻微升高和上升情况。算法整合了急性心肌梗死（AMI）临床症状出现时以及发病后1或3小时的hs-cTn测量值，以判断AMI患者是否患病。越来越多的即时检验（POC）cTn检测方法进入诊断市场，但在将此类POC检测方法实际应用于医院环境之前，需要进行全面的临床验证研究。本综述概述了心肌肌钙蛋白在AMI患者和健康人群中的技术方面以及诊断和预后用途。
